MAINZ, Germany, July 21, 2025 — BioNTech (Nasdaq: BNTX, referred to as “BioNTech” or “the Company”) is scheduled to release its financial outcomes for the second quarter of 2025 on Monday, August 4, 2025. On the same day, the Company will conduct a conference call and webcast, commencing at 8:00 a.m. EDT (2:00 p.m. CEST), accessible to investors, financial analysts, and the general public, to review its financial performance and offer a corporate briefing.
To participate in the live conference call via telephone, please register using the provided link. Once registered, dial-in numbers and a PIN will be supplied. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via the designated link.
Attendees can also find the slides and the webcast of the conference call on the “Events & Presentations” page within the Investor Relations section of the Company’s website at the specified address. A replay of the webcast will be made available shortly after the call concludes and will remain archived on the Company’s website for 30 days subsequent to the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) functions as a global, next-generation immunotherapy enterprise, spearheading the development of innovative investigative therapies for cancer and other serious conditions. BioNTech leverages a wide array of computational discovery and therapeutic approaches with the goal of expediting the development of novel biopharmaceuticals. Its diverse pipeline of oncology product candidates, designed to cover the entire continuum of cancer, includes mRNA cancer immunotherapies, advanced immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and pioneering chimeric antigen receptor (CAR) T cell therapies. Drawing on its profound expertise in mRNA development and internal manufacturing capabilities, BioNTech and its collaborators are engaged in the research and development of multiple mRNA vaccine candidates for various infectious diseases, in addition to its extensive oncology pipeline. BioNTech has forged a broad network of collaborations with numerous global and specialized pharmaceutical partners, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (a member of the Roche Group), Genevant, Genmab, MediLink, OncoC4, Pfizer, and Regeneron.
For additional information, please visit the official website.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Media Relations
Jasmina Alatovic
